Latest Breaking News On - Nanoparticle delivery system - Page 1 : comparemela.com

Genprex (GNPX) Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex (GNPX) Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMeharry medical collegeRodney varnerMitochondrial metabolism at meharry medical collegeGenprex incResearch agreementsRogel cancer center judith tamUniversity of michigan rogel cancer centerDrug administrationLung cancer research initiativeSponsored research agreementsMaterial transfer agreementsChief executive officerNanoparticle delivery systemMichigan rogel cancerMichigan rogel cancer center judith tam

Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.

United statesGenprex incVstock transferCompany websiteCompany board of directors theExchange commissionCompany boardPrnewswire genprex incNasdaq capitalNanoparticle delivery systemImmunogene therapyFast track designationLanguage concerning forward looking statementsPrivate securities litigation reform actAnnual reportNasdaq capital market

Genprex Announces 1-For-40 Reverse Stock Split Effective February 2, 2024

Genprex Announces 1-For-40 Reverse Stock Split Effective February 2, 2024
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesKalyn dabbsPrnewswire genprex incCompany board of directors theExchange commissionCompany websiteVstock transferGenprex incCompany boardNasdaq capitalNanoparticle delivery systemImmunogene therapyFast track designationPrivate securities litigation reform actAnnual reportNasdaq capital market

Genprex to Present at BIO-Europe 2023 Conference

/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.

United statesCatherine vaczyGenprex incExchange commissionPrnewswire genprex incCompany websiteExecutive vice presidentGeneral counselChief strategy officerChief strategyNanoparticle delivery systemFast track designationPrivate securities litigation reform actAnnual report

Genprex to Host a Virtual Key Opinion Leader Event on Bringing Gene Therapy to the Fight Against Lung Cancers

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will host a virtual key opinion leader (KOL) event highlighting the current state of lung cancer treatments and the challenges facing patients.

United statesDaniel morgenszternMarks bergerKalyn dabbsGenprex incCompany websiteExchange commissionResearch instituteGene therapyFight against lungRegistration linkVirginia cancer specialistsPhasei trial programJohns hopkins hospitalThoracic oncologyWashington university school